BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2019

View Archived Issues

TNFR2 is yang to TNFR1's yin

Read More

IL-13Rlalpha2 as a therapeutic target in inflammatory bowel disease

Read More

Adropin is correlated with erectile dysfunction in coronary artery disease patients

Read More

Fast skeletal muscle troponin activators can counter skeletal muscle fatigue

Read More

Triple kinase inhibitor IBL-302 shows promising activity in preclinical models of neuroblastoma

Read More

New sialyltransferase inhibitors synthesized at Radboud Universiteit Nijmegen

Read More

InnoCare Pharma patents indoleamine 2,3-dioxygenase 1 inhibitors

Read More

Initiator Pharma provides an update on IPED-2015 and IP-2018 development

Read More

Anti-LAG-3 fully human innovative antibody LBL-007 receives clinical approval

Read More

Decrease in tumor biomarkers seen in AIVITA's phase II study in patients with glioblastoma

Read More

Gritstone Oncology initiates phase I/II study of neoantigen-based therapeutic cancer vaccine

Read More

Positive topline results presented from ELIPSE HoFH phase III study of evinacumab

Read More

Themis Bioscience recruiting participants in phase I study of MV-ZIKA-RSP vaccine

Read More

H3R inverse agonist LML-134 demonstrates rapid brain penetration and fast kinetic profile

Read More

Pharmacokinetics and safety data presented from phase I study of EA-230

Read More

Sunshine Lake Pharma discovers sodium/glucose cotransporter 1 inhibitors

Read More

New dopamine D3 receptor antagonists synthesized at Shionogi

Read More

Cadila Healthcare identifies bacterial DNA topoisomerase II inhibitors

Read More

FDA approves new drug combination for highly drug-resistant tuberculosis

Read More

Rozlytrek approved by FDA or two new cancer indications

Read More

CARB-X awards funding to IBT to expand development of its IBT-V02 vaccine

Read More

Helmholtz Zentrum Munchen, Phio to identify new targets based on sd-rxRNA platform

Read More

CytoDyn provides update on its HIV dose-escalating monotherapy trial of leronlimab

Read More

Soligenix awarded grant to evaluate SGX-942 in pediatric indications

Read More

In dopamine D1 receptor combo, ghrelin is resurrected as Alzheimer's target

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing